Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer

Novel anti-EGFR therapies target resistance to standard-of-care anti-EGFR in patients with metastatic lung cancer. We describe tumors at progression versus at the initiation of novel anti-EGFR agents in patients with metastatic lung adenocarcinoma harboring EGFR mutation. This clinical case series r...

Descripción completa

Detalles Bibliográficos
Autores principales: Basse, Clémence, Trabelsi-Grati, Olfa, Masliah, Julien, Callens, Céline, Kamal, Maud, Freneaux, Paul, Klijanienko, Jerzy, Bieche, Ivan, Girard, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965794/
https://www.ncbi.nlm.nih.gov/pubmed/36835213
http://dx.doi.org/10.3390/ijms24043802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965794/
https://www.ncbi.nlm.nih.gov/pubmed/36835213
http://dx.doi.org/10.3390/ijms24043802

Ejemplares similares